09 Aug Ray Therapeutics
Posted at 19:48h
in
Jenny Holt, Chief Development Officer
Oct. 6 | 11:15am | FLW Ballroom F
San Francisco, CA
(Private)
Ray Therapeutics (RayTx) is a late-stage biopharmaceutical company advancing optogenetic therapies to restore vision to patients with retinal degenerative diseases, regardless of underlying genetic mutations. Following a Phase 1 study, RayTx was awarded RMAT and PRIME designations for its lead program, RTx-015, in retinitis pigmentosa. The program is now moving into a pivotal phase 2/3 study. RayTx’s second investigational product, RTx-021, is in clinic with a phase 1 study in Stargardt Disease, and will expand into a second indication, Geographic Atrophy, later this year.